Keeling K - Search Results

1

Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.

Staedtke V, Anstett K, Bedwell D, Giovannini M, Keeling K, Kesterson R, Kim Y, Korf B, Leier A, McManus ML, Sarnoff H, Vitte J, Walker JA, Plotkin SR, Wallis D. Staedtke V, et al. Among authors: keeling k. Clin Trials. 2024 Feb;21(1):51-66. doi: 10.1177/17407745231207970. Epub 2023 Nov 8. Clin Trials. 2024. PMID: 37937606 Free article.

2

Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.

Manuvakhova M, Keeling K, Bedwell DM. Manuvakhova M, et al. Among authors: keeling k. RNA. 2000 Jul;6(7):1044-55. doi: 10.1017/s1355838200000716. RNA. 2000. PMID: 10917599 Free PMC article.

3

Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.

Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Keeling KM, et al. Hum Mol Genet. 2001 Feb 1;10(3):291-9. doi: 10.1093/hmg/10.3.291. Hum Mol Genet. 2001. PMID: 11159948

4

Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.

Keeling KM, Bedwell DM. Keeling KM, et al. J Mol Med (Berl). 2002 Jun;80(6):367-76. doi: 10.1007/s00109-001-0317-z. Epub 2002 Jan 25. J Mol Med (Berl). 2002. PMID: 12072912

5

Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene.

Du M, Jones JR, Lanier J, Keeling KM, Lindsey JR, Tousson A, Bebök Z, Whitsett JA, Dey CR, Colledge WH, Evans MJ, Sorscher EJ, Bedwell DM. Du M, et al. J Mol Med (Berl). 2002 Sep;80(9):595-604. doi: 10.1007/s00109-002-0363-1. Epub 2002 Jul 3. J Mol Med (Berl). 2002. PMID: 12226741

6

Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae.

Keeling KM, Lanier J, Du M, Salas-Marco J, Gao L, Kaenjak-Angeletti A, Bedwell DM. Keeling KM, et al. RNA. 2004 Apr;10(4):691-703. doi: 10.1261/rna.5147804. RNA. 2004. PMID: 15037778 Free PMC article.

7

Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.

Du M, Keeling KM, Fan L, Liu X, Kovaçs T, Sorscher E, Bedwell DM. Du M, et al. J Mol Med (Berl). 2006 Jul;84(7):573-82. doi: 10.1007/s00109-006-0045-5. Epub 2006 Mar 16. J Mol Med (Berl). 2006. PMID: 16541275

8

Tpa1p is part of an mRNP complex that influences translation termination, mRNA deadenylation, and mRNA turnover in Saccharomyces cerevisiae.

Keeling KM, Salas-Marco J, Osherovich LZ, Bedwell DM. Keeling KM, et al. Mol Cell Biol. 2006 Jul;26(14):5237-48. doi: 10.1128/MCB.02448-05. Mol Cell Biol. 2006. PMID: 16809762 Free PMC article.

9

Eukaryotic release factor 1 phosphorylation by CK2 protein kinase is dynamic but has little effect on the efficiency of translation termination in Saccharomyces cerevisiae.

Kallmeyer AK, Keeling KM, Bedwell DM. Kallmeyer AK, et al. Among authors: keeling km. Eukaryot Cell. 2006 Aug;5(8):1378-87. doi: 10.1128/EC.00073-06. Eukaryot Cell. 2006. PMID: 16896221 Free PMC article.

10

Distinct eRF3 requirements suggest alternate eRF1 conformations mediate peptide release during eukaryotic translation termination.

Fan-Minogue H, Du M, Pisarev AV, Kallmeyer AK, Salas-Marco J, Keeling KM, Thompson SR, Pestova TV, Bedwell DM. Fan-Minogue H, et al. Among authors: keeling km. Mol Cell. 2008 Jun 6;30(5):599-609. doi: 10.1016/j.molcel.2008.03.020. Mol Cell. 2008. PMID: 18538658 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters